FMC Corp is not a strong buy for a beginner investor with a long-term focus at this time. While there are positive developments such as the strategic agreement with Corteva, the stock's technical indicators, analyst ratings, and lack of recent trading signals suggest a cautious approach. The stock's recent price decline and bearish moving averages indicate potential downside risk, and the company's financial stress, as noted by analysts, adds further uncertainty.
The MACD is positive and expanding, but the RSI is neutral at 43.742, showing no clear momentum. The moving averages are bearish (SMA_200 > SMA_20 > SMA_5), and the stock is trading near its pivot level of 11.622, with key resistance at 12.368 and support at 10.875. This suggests limited upside potential in the short term.

The strategic supply agreement with Corteva, including a $200 million pre-purchase, positions FMC well for long-term growth in the herbicide market. The dual mode of action herbicide technology could enhance productivity and profitability for farmers.
Analyst concerns about financial stress, rising input costs, and restructuring challenges weigh heavily on the stock. The Middle East conflict has added pressure to input costs, and the company's credit agreement amendments signal downside risk to earnings.
No financial data is available for the latest quarter, but analysts have flagged concerns about financial stress and restructuring delays.
Analyst ratings are mixed, with some raising price targets (e.g., Goldman Sachs to $21) and others downgrading the stock (e.g., Vertical Research to Underperform). The consensus is largely Neutral, reflecting uncertainty about the company's near-term prospects.